Regenerative Therapies Library

Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.

All Library Articles Presentations Spotlights News

Showing 1–24 of 150

LifeSpan.ioMar 26, 2026

Cellular Senescence and Senotherapeutics: The Expert Roundup

Cellular senescence—the accumulation of cells that cease dividing but resist death—has emerged as a primary target in longevity medicine due to evidence that clearing these cells extends healthspan and can address root causes of age-related disease. Senotherapeutics, including senolytics and senomorphics, are transitioning from preclinical studies to clinical trials, though significant challenges in biomarker standardization, cellular heterogeneity, and clinical efficacy remain.

Nature - npj AgingMar 10, 2026

Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming

Senotherapeutics—strategies that eliminate or reprogram senescent cells—represent a shift from broad-spectrum senolytic approaches toward precision interventions that target specific cell types and contexts. This progression directly addresses a fundamental mechanism of aging, offering potential to extend healthspan by restoring cellular function rather than relying solely on senescent cell elimination.

LifeSpan.ioMar 27, 2026

Mitochondria Delivery Method Rescues Parkinson’s in Mice

Researchers encapsulated healthy mitochondria in red blood cell membranes to deliver them into diseased cells, achieving efficient uptake and functional restoration across multiple cellular models of mitochondrial dysfunction. This addresses a long-standing barrier in mitochondrial replacement therapy and demonstrates potential for treating mitochondrial diseases and age-related energy decline.

LT WireMay 15, 2026

Klotho Cell Therapy Restores Aging Protein via Encapsulation

Avaí Bio will present clinical data on an encapsulated cell therapy designed to restore circulating α-Klotho, a protein implicated in aging and metabolic regulation. The approach uses Austrianova's Cell-in-a-Box technology to sustain Klotho production, addressing a mechanism that declines with age and correlates with multiple age-related pathologies.

Longevity.TechnologyFeb 24, 2026

Klothea initiates longevity-focused human trial of klotho therapy

Klothea Bio has initiated a Phase 1b trial of AKL003, an mRNA therapy designed to elevate circulating alpha klotho protein levels in healthy adults. The trial represents a direct approach to testing whether increased klotho—a protein associated with organ protection and repair across multiple physiological systems—can favorably shift biomarkers linked to human lifespan and biological age.

LT WireApr 24, 2026

Springfield Wellness Center marks 25 years of NAD+ IV therapy

Springfield Wellness Center has operated for 25 years using intravenous NAD+ therapy as part of a multimodal protocol for addiction recovery and brain restoration. The clinic's longevity and expansion suggest sustained clinical utility, though the evidence base and mechanistic clarity for NAD+ infusions in longevity contexts remain limited.

Longevity.TechnologyApr 13, 2026

Microcap produces anti-aging protein from encapsulated cells

Klothonova is developing an encapsulated cell therapy designed to restore circulating α-Klotho, a protein that declines with age and influences cardiovascular, renal, and cognitive function. The approach uses genetically modified cells housed in a biocompatible capsule to sustainably produce the protein, addressing a mechanism implicated in multiple age-related conditions.

Longevity.TechnologyMar 25, 2026

Stem cell review targets diabetic wound healing

A systematic review and meta-analysis of allogeneic mesenchymal stromal cell therapies for diabetic foot ulcers found higher rates of complete wound closure and greater reductions in wound size compared to standard care, with no clear signal of serious treatment-related adverse events. The work demonstrates that regenerative cell therapies may support the body's repair capacity when conventional approaches alone prove insufficient in metabolic disease.

Longevity.TechnologyMar 4, 2026

Cenegenics expands advanced plasma exchange services in Beverly Hills

Cenegenics has introduced selective plasma exchange technology designed to remove inflammatory proteins, metabolic byproducts, and environmental toxins while preserving beneficial plasma components. The service positions itself as a preventative intervention for individuals managing chronic environmental exposures and systemic inflammation.

Longevity.TechnologyApr 10, 2026

Mitrix moves mitochondria into the clinic

Mitrix Bio has reported preliminary Phase 1 safety data from mitochondrial transplantation in two older adults with no observed adverse effects, while simultaneously launching clinics offering the intervention under Right to Try frameworks. This represents a transition from preclinical work to early clinical deployment, though data density remains limited relative to narrative momentum.

Wiley Aging CellApr 14, 2026

Clearance of Senescent Cells by BCLXL‐PROTAC: A Novel Approach to Treat COPD?

BCL XL-PROTAC, a senolytic agent, selectively eliminates senescent cells in COPD airway tissue while promoting proliferation of healthy cells. This approach addresses a core driver of age-related lung disease and suggests a therapeutic pathway for restoring lung cell function in COPD patients.

Longevity.TechnologyMar 5, 2026

Avaí Bio–Austrianova’s longevity protein program enters production

Avaí Bio and Austrianova have begun GMP-compliant production of a Master Cell Bank for genetically modified cells engineered to overexpress α-Klotho, a protein associated with improved cognitive resilience and organ function in aging. This transition from research to scalable manufacturing represents a critical step toward clinical cell therapy delivery for age-related disease.

Longevity.TechnologyMar 26, 2026

GARM expands gene therapy platform with Klotho

GARM Clinic has added Klotho to its non-permanent gene therapy platform alongside Follistatin and VEGF, positioning itself as a clinical destination for early-stage longevity interventions. Klotho addresses age-related decline in the protein's natural production, targeting mitochondrial function, metabolic resilience, and systemic health markers that degrade with age.

LifeSpan.ioApr 24, 2026

Reprogrammed Cardiomyocytes Soften the Blow in Heart Attack

Partial reprogramming of heart muscle cells using three Yamanaka factors (OCT4, SOX2, KLF4) enables cardiomyocytes to complete cell division after myocardial infarction in mice by dismantling their contractile scaffold without triggering uncontrolled proliferation. This approach addresses a fundamental barrier to cardiac regeneration: mature heart cells lose divisibility because their rigid internal structure prevents cytokinesis, even when DNA replication is initiated.

Longevity.TechnologyFeb 9, 2026

New peptide drugs on the horizon with PepLib–Lilly collab

Eli Lilly and PepLib Biotech have formed a collaboration to develop peptide-based therapeutics designed to target specific disease pathways with precision. Peptides represent a distinct therapeutic modality with applications in age-related conditions, metabolic dysfunction, and cardiovascular disease—key drivers of healthspan and lifespan limitations.

Longevity.TechnologyFeb 13, 2026

MDLifespan and Cenegenics expand toxin-clearing therapy

MDLifespan and Cenegenics are expanding access to Therapeutic Plasma Exchange (TPE), a procedure that removes environmental toxins, microplastics, and heavy metals from circulation to reduce chronic inflammation. The partnership positions toxin clearance as a foundational longevity strategy, addressing inflammation that undermines cognitive, metabolic, and cardiovascular function.

LT WireMay 4, 2026

LifespanningRx launches partner program for peptide therapy

LifespanningRx introduced a Partner Program enabling non-clinical businesses to offer peptide therapy through clinician oversight, pharmacy fulfillment, and white-label infrastructure. This addresses a gap in scalable delivery of peptide-based interventions within the broader precision medicine ecosystem.

Wiley Aging CellMar 6, 2026

Decreased Glucose Metabolism and Declined Chaperones Are Unique Features Required for the Survival of Senescent Fibroblasts and Pyruvate Dehydrogenase Is a Potent Senolytic Target

Senescent fibroblasts depend on reduced glucose metabolism and maintained chaperone proteins for survival. Inhibiting pyruvate dehydrogenase selectively eliminates senescent cells, including therapy-induced senescent cancer cells, with synergistic enhancement when combined with chaperone inhibition.

LifeSpan.ioFeb 13, 2026

Cellular Reprogramming Rescues Memory-Encoding Neurons

Partial cellular reprogramming using three Yamanaka factors (OSK) successfully restored memory function in aged mice and Alzheimer's disease models by rejuvenating memory-encoding neurons while preserving their neuronal identity. This approach demonstrates that targeted reprogramming of engram cells can reverse age-related cognitive decline without causing dedifferentiation or memory loss.

Nature AgingApr 1, 2026

Stem cell therapy might improve aging frailty

Stem cell therapy demonstrates potential to address frailty in aging by restoring cellular repair capacity and tissue regeneration. This approach targets a fundamental mechanism of aging decline rather than managing symptoms.

Peter Attia MDApr 13, 2026

#387 – AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field

Peptides represent a legitimate therapeutic class with demonstrated efficacy, but clinical validation is confined to a narrow subset of compounds. Most peptide applications currently marketed fall outside evidence-supported use, requiring practitioners to distinguish between established interventions and speculative applications.

LifeSpan.ioFeb 27, 2026

Cellular Reprogramming: The Expert Roundup

Cellular reprogramming—the process of resetting aged cells to younger functional states through partial application of reprogramming factors—represents a fundamental shift in how aging is understood: not as irreversible damage accumulation, but as a modifiable biological state. Clinical trials are imminent, and the field has moved from theoretical elegance to therapeutic platform with potential applications across age-associated diseases.

Nature AgingFeb 3, 2026

Precision targeting of the SASP in cancer therapy

TGFβ signaling emerges as the primary tumor-promoting mechanism within senescent cells induced by platinum chemotherapy in ovarian and lung cancers. Targeting this pathway selectively could preserve the therapeutic benefit of chemotherapy while blocking its pro-tumor effects, addressing a critical vulnerability in current cancer treatment.

LifeSpan.ioMar 30, 2026

How a Growth Factor and SIRT1 Might Combat Disc Degeneration

FGF21, a growth factor that declines with age, delays intervertebral disc degeneration by upregulating SIRT1 and restoring mitochondrial quality control through the PINK1-Parkin mitophagy pathway. This mechanism addresses a primary driver of age-related lower back pain by counteracting cellular senescence in disc tissue.

Biological EDGE

Biohacking Starts With NO